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Abstract
Background: Envenomation by crotaline snakes (rattlesnake, cottonmouth, copperhead) is a complex, potentially
lethal condition affecting thousands of people in the United States each year. Treatment of crotaline
envenomation is not standardized, and significant variation in practice exists.
Methods: A geographically diverse panel of experts was convened for the purpose of deriving an evidence-
informed unified treatment algorithm. Research staff analyzed the extant medical literature and performed targeted
analyses of existing databases to inform specific clinical decisions. A trained external facilitator used modified
Delphi and structured consensus methodology to achieve consensus on the final treatment algorithm.
Results: A unified treatment algorithm was produced and endorsed by all nine expert panel members. This
algorithm provides guidance about clinical and laboratory observations, indications for and dosing of antivenom,
adjunctive therapies, post-stabilization care, and management of complications from envenomation and therapy.
Conclusions: Clinical manifestations and ideal treatment of crotaline snakebite differ greatly, and can result in
severe complications. Using a modified Delphi method, we provide evidence-informed treatment guidelines in an
attempt to reduce variation in care and possibly improve clinical outcomes.
Background
Envenomation by pit vipers (family Viperidae, subfamily
Crotalinae, genera Crotalus, Agkistrodon, and Sistrurus)
is a dynamic and potentially serious medical condition.
Approximately 9,000 patients are treated for snakebite
and 5 die in the United States (US) each year [1,2]. The
use of antivenom is increasing over time. Forty-four per-
cent of patients whose cases were reported to US poison
centers in 2007 were treated with antivenom, a signifi-
cant increase from 30% in 2000 [3]. The proportion of
patients receiving antivenom varies more than 5-fold
between states. Poison center data suggest a case-fatality
rate among rattlesnake victims of approximately 1 death
per 736 patients [4].
The clinical manifestations of crotaline envenomation
vary considerably based on a complex interplay between
the victim and the venom exposure. Some critical mani-
festations, such as airway involvement and anaphylaxis
to venom, are so uncommon that few clinicians gain
experience managing these findings. To our knowledge,
all extant treatment algorithms were created by a single
author or by a small group of authors with similar
experience [5-8]. Many algorithms are specific for the
treatment of subpopulations of crotaline victims, such as
children or those envenomated in regions where copper-
head snakes predominate. Few authors describe their
methods for algorithm development, and many algo-
rithms do not fully describe post-stabilization care. Sig-
nificant variations in practice exist; two studies
demonstrate that the proportion of snakebite victims
who undergo fasciotomy is five times greater in an insti-
tution where snakebite victims are managed primarily
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by surgeons, compared to an institution where snakebite
victims are admitted and managed primarily by medical
toxicologists [9,10]. Antivenom is expensive (current
wholesale cost greatly exceeds US$1,000/vial) and asso-
ciated with immunologic risk, and it is imperative for
the physician to use this resource wisely. The objective
of this project was to produce an evidence-informed
unified treatment algorithm for pit viper snakebite man-
agement in the US, with the goal of reducing unneces-
sary variations in practice and improving outcomes for
snake envenomation victims.
Methods
Because only one randomized clinical trial involving the
treatment of crotaline snakebite with antivenom has
ever been published, a formal meta-analysis could not
be used for rule development [11]. A standardized evi-
dence-based rule development process, such as that pro-
posed by the GRADE working group, cannot be used to
develop an algorithm because the clinical questions can-
not be defined in advance. Therefore, using a trained
external facilitator, we used structured methods to
achieve an evidence-informed consensus among a
diverse group of experts.
Two authors (EJL, RCD) recruited panel members
based on their published envenomations research and
clinical experience. In order to ensure a diversity of
experience, panel members were chosen from across the
regions of the US where crotaline envenomations are
common, with no more than one panel member chosen
from the same geographic area. A group size of nine
experts was chosen to permit the required diversity of
experience while keeping the consensus-building process
manageable. One of the original panel members (SCC)
had to withdraw from the process; he was replaced on
the panel by a colleague from the same institution, but
remained involved in the project as a non-voting partici-
pant and contributor. The nine panel members have
extensive clinical experience managing crotaline snake-
bite in a variety of clinical settings (Table 1), and have
published 57 peer-reviewed articles on the subject. One
additional author (EJL) participated in the panel meeting
but did not vote.
The consensus process was managed by a professional
facilitator (David Kovick, JD, Consensus Building Insti-
tute, Cambridge, MA). Competing interests of all parti-
cipants were disclosed prior to decision-making. One
author (EJL) created an initial “straw man” draft algo-
rithm, which was distributed to all panelists. The draft
algorithm identified key decision points in the treatment
process, posed questions about best treatment practices,
and served as a starting point for discussion. Initial
modifications to the “straw man” were processed using
a modified Delphi methodology, through which panelists
provided substantive feedback through the facilitator.
The revised algorithm was presented to the panel in a
90-minute webinar, where facilitated discussion was
used to identify initial areas of consensus and prioritize
issues requiring further discussion. A second round of
modified Delphi revisions was then completed. Final
algorithm development took place during a 1.5-day in-
person meeting held in Denver, Colorado, in May, 2010,
which was governed by a structured consensus-building
process. In resolving points of divergence among panel
members, the panel relied upon published data (where
available), supported by the collective experience of
panel members. Consensus was defined as unanimous
agreement of all panel members. After minor text revi-
sions, the final algorithm was sent to panelists electroni-
cally for a conclusive vote.
In order to provide the panel members with a com-
plete literature base, research staff performed a struc-
tured literature search to identify articles relevant to the
treatment of crotaline snakebite in the United States,
using the search strategy in Table 2. Two researchers
reviewed the titles and abstracts of all articles to identify
those which might contain original data about (a) the
management of crotaline snakebite with the current
(ovine Fab) antivenom or (b) the management of crota-
line snakebite without antivenom. In the event of dis-
agreement, the article was pulled and reviewed. Full text
copies of the 42 articles containing original data relevant
to the key questions identified in preliminary panel
deliberations were obtained and provided for panel
members’ use during deliberations.
Recurrence of one or more venom effects (local pain and
swelling and/or hematologic abnormalities such as coagu-
lopathy and thrombocytopenia) following successful initial
treatment with antivenom is a known problem in the
management of venomous snakebite. Early issue identifica-
tion revealed that prevention and treatment of these recur-
rence phenomena was a topic with some disagreement.
Four data sources were utilized to inform the panel discus-
sion of this issue. Statisticians reanalyzed raw data from
databases created in the premarketing studies of the cur-
rent antivenom to extract specific information about
recurrence phenomena [11,12]. The same statistical team
reanalyzed raw data from databases created in a phase IV
post-marketing study of Fab antivenom to extract specific
information about recurrence phenomena [13]. The
research team reviewed the results of the literature search
to identify and summarize all articles containing data
about recurrence phenomena. These three data sources
were prepared into resource documents for the panel
members. During the in-person meeting, two authors pro-
vided formal presentations. One panelist (AMR) analyzed
and presented case-level data about recurrence phenom-
ena observed at her center, while a second participant
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(EJL) presented a structured review of the literature related
to recurrence phenomena. In addition, three panelists pro-
vided informal presentations. One panelist (SAS) pre-
sented an analysis of the prognostic significance of fibrin
split products in the identification of patients at risk for
late hematologic effects, while two other panelists (SPB
and WB) presented data about recurrence phenomena at
their centers.
Role of the funding source
This was an investigator-initiated project conceived,
designed, and executed by two authors (EJL and RCD)
Table 1 Panel Member Qualifications
Panel Member Board Certification Practice Setting Practice Location
William Banner, MD, PhD Pediatrics, pediatric critical care, medical
toxicology
Clinical toxicology service,
pediatric intensive care unit
Oklahoma City,
Oklahoma, USA
Vikhyat Bebarta, MD Emergency medicine, medical toxicology Clinical toxicology service, emergency
department
San Antonio, Texas, USA
Jeffrey Bernstein, MD Emergency medicine, medical toxicology,
clinical pharmacology
Emergency department, poison center Miami, Florida, USA
Sean P. Bush, MD Emergency medicine Envenomations clinical service, emergency
department
Loma Linda,
California, USA
Richard C. Dart, MD Emergency medicine, medical toxicology Clinical toxicology service, poison center Denver, Colorado, USA
William P. Kerns, II, MD Emergency medicine, medical toxicology Clinical toxicology service,
emergency department, poison center
Charlotte, North
Carolina, USA
William H. Richardson,
MD
Emergency medicine, medical toxicology Emergency department, poison center Columbia, South Carolina,
USA
Anne-Michelle Ruha, MD Emergency medicine, medical toxicology Clinical toxicology service,
emergency department, poison center
Phoenix, Arizona, USA
Steven A. Seifert, MD Emergency medicine, medical toxicology Clinical toxicology service,
emergency department, poison center
Albuquerque, New Mexico,
USA
David A. Tanen, MD Emergency medicine, medical toxicology Clinical toxicology service,
emergency department, poison center
San Diego,
California, USA
Table 2 Search Strategy
Database Pub Med Ovid Medline EMBASE
Dates searched 1/1/1990 - 12/31/2009 1/1/1990 - 12/31/2009 1990 - 2009
Search terms employed (all connected by logical
“OR” function)
MeSH headings: MeSH headings:
Crotalid venoms/PO
[poisoning]
Crotalid venoms/PO
[poisoning]
Crotalid venoms AND [intoxication
OR toxicity]
Crotalid venoms/TO
[toxicity]
Crotalid venoms/TO
[toxicity]
Snake venoms AND [intoxication OR
toxicity]
Snake venoms/PO Snake venoms/PO Snake bites AND [drug therapy OR
therapy]
Snake venoms/TO Snake venoms/TO
Snake bites/DT [drug
therapy]
Snake bites/DT [drug
therapy]
Viperidae
Snake bites/TH
[therapy]
Snake bites/TH
[therapy]
Agkistrodon
Viperidae Viperidae Crotalus
Agkistrodon Agkistrodon FabAV
Crotalus Crotalus Crotaline immune Fab
Keywords Keywords
CroFab CroFab
Crotaline immune Fab Crotaline immune Fab
Citations retrieved 1230 1097 1711
Searches were conducted on January 6, 2010 and were limited to English language and humans. After removal of 1,748 duplicate citations, 339 additional
citations were excluded based on the keywords rat(s), mouse, mice, rabbit(s), cellular, in vivo, or in vitro. Hand-search of the titles and abstracts of the remaining
1,951 citations yielded 91 citations that appeared to contain original data about crotaline snake envenomation patients who were either treated with Fab
antivenom or managed without antivenom. Full-text copies of these 91 articles and abstracts were obtained and made available to the project team in a
computer data file. Of these, 42 articles and abstracts were identified as containing data relevant to the key questions identified in preliminary panel discussions.
These 42 references were reproduced and made available during the in-person panel meeting.
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and other Rocky Mountain Poison and Drug Center
staff. The antivenom manufacturer provided funding
support. Sponsor representatives were not present dur-
ing the webinar or panel discussions. Sponsor represen-
tatives reviewed the final manuscript before publication
for the sole purpose of identifying proprietary informa-
tion. No modifications of the manuscript were requested
by the manufacturer.
Results
Final unified treatment algorithm
The unified treatment algorithm is shown in Figure 1.
The final version was endorsed unanimously. Specific
considerations endorsed by the panelists are as follows:
Role of the unified treatment algorithm (general
considerations and box 16)
This algorithm pertains to the treatment of human
patients bitten by pit viper snakes (family Viperidae,
subfamily Crotalinae) in the US, including the rattle-
snakes (genus Crotalus), pygmy rattlesnakes (Sistrurus),
and moccasin snakes (genus Agkistrodon). Within the
Agkistrodon genus are the copperhead snakes (A. contor-
trix) and the water moccasin (cottonmouth) snake
(A. piscivorus). This algorithm does not apply to
treatment of patients bitten by coral snakes (family Ela-
pidae), nor by snakes that are not indigenous to the US.
At the time this algorithm was developed, the only
antivenom commercially available for the treatment of
pit viper envenomation in the US is Crotalidae Polyva-
lent Immune Fab (ovine) (CroFab®, Protherics, Nash-
ville, TN). All treatment recommendations and dosing
apply to this antivenom. This algorithm does not con-
sider treatment with whole IgG antivenom (Antivenin
(Crotalidae) Polyvalent, equine origin (Wyeth-Ayerst,
Marietta, Pennsylvania, USA)), because production of
that antivenom has been discontinued and all extant
lots have expired. This antivenom also does not consider
treatment with other antivenom products under devel-
opment. Because the panel members are all hospital-
based physicians, the panel did not evaluate field first
aid or other prehospital therapy.
In order to create an algorithm that was simple
enough to be used effectively, the panel decided not to
include specific recommendations for the management
of certain rare manifestations of crotaline snakebite.
These included snakebites to the head and neck, snake-
bites causing rhabdomyolysis, and apparent anaphylactic
or anaphylactoid reactions to venom. In addition the
panel recognized that no treatment algorithm could
Emergency Department and Hospital Management of Pit Viper Snakebite
Includes: Rattlesnakes, Copperheads, and Cottonmouths (Water Moccasins)
Assess Patient
Mark leading edge of swelling and tenderness every 15-30 minutes
Immobilize and elevate extremity
Treat pain (IV opioids preferred)
Obtain initial lab studies (protime, Hgb, platelets, fibrinogen)
Update tetanus
Contact poison control center (1-800-222-1222)
Check for Signs of Envenomation
Swelling, tenderness, redness, ecchymosis, or blebs at the bite site, or
Elevated protime; decreased fibrinogen or platelets, or
Systemic signs, such as hypotension, bleeding beyond the puncture site, 
refractory vomiting, diarrhea, angioedema, neurotoxicity
Apparent Dry Bite / No Bite
Do not administer antivenom
Observe patient ? 8 hours
Repeat labs prior to discharge
If patient develops signs of 
envenomation, return to box 2
Check for Indications for Antivenom
Swelling that is more than minimal and that is progressing, or
Elevated protime; decreased fibrinogen or platelets, or
Any systemic signs
Apparent Minor Envenomation
Do not administer antivenom
Observe patient 12-24 hours
Repeat labs at 4-6 hours and prior to 
discharge
If patient develops progression of any 
signs of envenomation, return to box 3
Determine if Initial Control of Envenomation
has been Achieved
Swelling and tenderness not progressing
Protime, fibrinogen, and platelets normal or clearly improving
Clinically stable (not hypotensive, etc.)
Neurotoxicity resolved or clearly improving
Administer Antivenom
Establish IV access and give IV fluids
Pediatric antivenom dose = adult dose
Mix 4-6 vials of crotaline Fab antivenom (CroFab®) in 250 ml NS and infuse IV over 1 
hour
For patients in shock or with serious active bleeding
Increase initial dose of antivenom to 8-12 vials
Call physician expert (see box 12)
Initiate first dose of antivenom in ED or ICU
For suspected adverse reaction: hold infusion, treat accordingly, and call 
physician-expert
Re-examine patient for treatment response within 1 hour of completion of antivenom 
infusion
Repeat antivenom until
initial control is achieved.
If initial control is not achieved after 2 
doses of antivenom, call physician expert 
(see box 12)
Monitor Patient
Perform serial examinations
Maintenance antivenom therapy may be indicated
Read Box 13 (Maintenance Antivenom Therapy)
Observe patient 18-24 hours after initial control for progression of any venom effect
Follow-up labs 6-12 hours after initial control and prior to discharge
If patient develops new or worsening signs of envenomation, administer additional 
antivenom per box 4
Determine if Patient Meets Discharge Criteria
No progression of any venom effect during the specified observation period
No unfavorable laboratory trends in protime, fibrinogen, or platelets
Present
Present
None
None
Yes
No
Yes
See Post-Discharge Planning (box 14)
1
6
5
4
3
2
7
8
11
10
9
When to Call a Physician-Expert
Direct consultation with a physician-expert is recommended in 
certain high-risk clinical situations:
Life-threatening envenomation
Shock
Serious active bleeding
Facial or airway swelling
Hard to control envenomation
Envenomation that requires more than 2 doses of 
antivenom for initial control
Recurrence or delayed-onset of venom effects
Worsening swelling or abnormal labs (protime, 
fibrinogen, platelets, or hemoglobin) on follow-up visits
Allergic reactions to antivenom
If transfusion is considered
Uncommon clinical situations
Bites to the head and neck
Rhabdomyolysis
Suspected compartment syndrome
Venom-induced hives and angioedema
Complicated wound issues
If no local expert is available, a physician-expert can be reached 
through a certified poison center (1-800-222-1222) or the 
antivenom manufacturer’s line (1-877-377-3784).
Notes:
All treatment recommendations in this algorithm refer to 
crotalidae polyvalent immune Fab (ovine) (CroFab®).
This worksheet represents general advice from a panel of US 
snakebite experts convened in May, 2010. No algorithm can 
anticipate all clinical situations. Other valid approaches exist, 
and deviations from this worksheet based on individual patient 
needs, local resources, local treatment guidelines, and patient 
preferences are expected. This document is not intended to 
represent a standard of care. For more information, please see 
the accompanying manuscript, available at 
www.biomedcentral.com.
Treatments to Avoid in
Pit Viper Snakebite
Cutting and/or suctioning of the wound
Ice
NSAIDs
Prophylactic antibiotics
Prophylactic fasciotomy
Routine use of blood products
Shock therapy (electricity)
Steroids (except for allergic phenomena)
Tourniquets
Maintenance Antivenom Therapy
Maintenance therapy is additional antivenom given after 
initial control to prevent recurrence of limb swelling
Maintenance therapy is 2 vials of antivenom Q6H x 3 
(given 6, 12, and 18 hours after initial control)
Maintenance therapy may not be indicated in certain 
situations, such as
Minor envenomations
Facilities where close observation by a physician-
expert is available.
Follow local protocol or contact a poison center or 
physician-expert for advice. 
Post-Discharge Planning
Instruct patient to return for
Worsening swelling that is not relieved by elevation
Abnormal bleeding (gums, easy bruising, melena, etc.)
Instruct patient where to seek care if symptoms of serum 
sickness (fever, rash, muscle/joint pains) develop
Bleeding precautions (no contact sports, elective surgery or 
dental work, etc.) for 2 weeks in patients with
Rattlesnake envenomation
Abnormal protime, fibrinogen, or platelet count at any 
time
Follow-up visits:
Antivenom not given:
PRN only
Antivenom given:
Copperhead victims: PRN only
Other snakes: Follow up with labs (protime, 
fibrinogen, platelets, hemoglobin) twice (2- 3 
days and 5-7 days), then PRN
12
13
14
15
16
Figure 1 Unified Treatment Algorithm for the Management of Pit Viper Snakebite in the United States.
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provide ideal advice for all situations or serve as a sub-
stitute for clinical judgment. Legitimate variations in
practice will always exist, and care may appropriately
vary based on several factors, including patient presenta-
tion, available treatment resources, patient comorbid-
ities, and patient preference. The panel explicitly
determined that the consensus treatment algorithm is
not a standard of care.
Patient assessment and initial management (box 1)
The initial approach to management of a patient with
suspected pit viper snake envenomation begins with his-
tory, physical examination, and measurement of vital
signs. Palpation of the envenomated area and marking
the leading edge of swelling and tenderness every 15 -
30 minutes is a useful way to determine whether local
tissue effects have stabilized or are progressing [7].
Although not evidence based, the panel recommends
immobilization and elevation of the envenomated extre-
mity to reduce swelling. In order to avoid obstructing
lymphatic outflow, speed resolution of swelling, and
possibly reduce the risk of blister formation in flexor
creases, major joints such as the elbow should be main-
tained in relative extension (≤ 45 degrees of flexion).
Opioids are preferred over non-steroidal anti-inflam-
matory drugs (NSAIDs) because of the theoretical risk
of bleeding associated with NSAID use in patients who
may develop coagulopathy or thrombocytopenia due to
envenomation. Although Clostridium tetani infection
has not been reported following crotaline snakebite, it
has occurred following envenomation by other vipers
[14,15]. Standard recommendations for tetanus booster
immunization (DTaP, Tdap, or Td as appropriate for
the patient’s age) should be followed [16].
Notification of a certified poison center is recom-
mended for all cases of snake envenomation, for two
reasons. First, poison center personnel can identify
situations where use of this algorithm may be inap-
propriate, and can provide treatment recommendations
based on local snake species and medical treatment
resources. Second, certified poison centers provide de-
identified data to the National Poison Data System,
which is used by public health professionals and policy-
makers. In the US, access to a certified poison center
can be made through a single, toll-free number: 1-800-
222-1222.
Signs of crotaline envenomation (box 2)
Approximately 80% of pit viper bites result in the injec-
tion of venom [17,18]. Pit viper venom is a complex mix-
ture of proteins and other macromolecules, with more
than 50 identified components. The clinical effects pro-
duced by envenomation can be broadly classified into
three groups. Local tissue effects include soft tissue
necrosis and chemically mediated inflammation. A num-
ber of venom components, including myotoxic phospho-
lipases A2 such as crotoxin, venom metalloproteinases
that activate tumor necrosis factor-alpha (TNF-a), myo-
toxin a, hyaluronidase, phosphomonoesterase, phospho-
diesterase, arginine ester hydrolase, and histamine- and
bradykinin-like factors, cause direct tissue injury and pro-
duce a broad cytokine response in the victim [7,19-22].
Clinically, these effects are evident as pain, redness, swel-
ling, tenderness, and myonecrosis that begin adjacent to
the bite site and spread with movement of the venom
through the lymphatic system. More than 90% of enveno-
mated pit viper victims develop local tissue effects [7].
Hematologic venom effects include fibrinogen degradation
and platelet aggregation and destruction [23,24]. On a
laboratory basis, these are manifest by decreased fibrino-
gen levels, elevated prothrombin time, and thrombocyto-
penia. Detection of fibrin split products may be an early
sign of a hematologic venom effect, and is a sensitive pre-
dictor of subsequent coagulopathy. In prospective stu-
dies, the presence of fibrin split products within the first
12 hours of treatment predicted subsequent hypofibrino-
genemia with 87% sensitivity and 69% specificity [25]. In
some patients, elevated fibrin split products were the
only early signs of developing hypofibrinogenemia. Clini-
cally, oozing of blood from the bite site and ecchymosis
of the surrounding tissue are common. Systemic bleeding
may manifest as nuisance bleeding, such as gingival
bleeding or haemolacria, or more serious bleeding, such
as significant epistaxis, gastrointestinal bleeding, or intra-
cranial hemorrhage. Even among the population with
severe defibrination or thrombocytopenia, most patients
do not develop medically significant bleeding [26]. How-
ever, severe and fatal bleeding complications have been
reported [27-31]. Systemic venom effects include hypoten-
sion from direct cardiovascular toxicity, third-spacing
and vasodilatation, nausea and vomiting, angioedema,
and neurotoxicity. Many pit vipers envenomations can
cause patients to experience a metallic taste and localized
neuromuscular effects (fasciculation and myokymia).
Severe systemic neurotoxicity induced by Mojave toxin
A, including cranial neuropathy and flaccid paralysis, are
frequent manifestations from Mojave rattlesnake (Crota-
lus scutulatus) and Southern Pacific rattlesnake (C. hel-
leri) envenomation, but have been rarely reported
following envenomation by other US rattlesnake species
[32-34]. Even within the same species, significant regional
variations exist in neurotoxic venom components [35].
In practice, the treating physician can assess for all of
these venom effects with a focused history and physical
examination and review of basic laboratory studies.
Serial measurements of prothrombin time, hemoglobin,
and platelet counts are recommended for all pit viper
victims. Fibrinogen is a more sensitive measure of
Lavonas et al. BMC Emergency Medicine 2011, 11:2
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venom-induced defibrination than prothrombin time,
and should be followed, if obtainable. Although one-
time measurement of fibrin split products in the first
12 hours post-bite is useful for early detection of incipient
hematologic venom effects, no proven role in therapy has
been established for serial fibrin split product measure-
ments, and an elevated FSP alone is not an indication for
antivenom treatment [25].
Most treatment resources include a grading scale for
crotaline envenomation. The reliability and validity of
these scales have not been established. Furthermore,
because snake envenomation is a dynamic disease state,
grading assigned at a single point in time may be a poor
representation of overall severity. The panel members
unanimously concluded that these scales are of little
value outside of a research context, and therefore did
not include a grading scale in these recommendations.
Instead, the panel recommends serial examination of the
patient for specific venom effects, with treatment based
on the evolution of medically significant venom effects
over time.
Indications for antivenom (box 3)
Administration of antivenom, in adequate doses, effec-
tively halts the spread of local tissue effects, reduces
hematologic venom effects, and reduces systemic effects
resulting from crotaline envenomation [11,12,26,36,37].
Treatment with antivenom is indicated for any patient
with progressive local tissue effects, hematologic venom
effects, and systemic signs attributable to venom. The
panel recommends withholding antivenom from patients
with limb envenomations who have localized pain and
swelling as the only manifestation of envenomation, pro-
vided that these local tissue effects are not progressing.
For extremity envenomations, some panelists use a
threshold of swelling that has crossed a major joint
[wrist, elbow, ankle, or knee] and is progressing for this
purpose, while other panelists treat minor hand enveno-
mations more aggressively. Unfortunately, it is not
known whether early administration of antivenom in a
patient with apparently minor envenomation improves
long-term limb functional outcomes [38]. Regardless of
the threshold chosen, patients with apparently minor
envenomations require close observation, and should
be given antivenom promptly if venom effects are
progressing.
Because hematologic venom effects can progress over
time, all patients seen early after envenomation with sig-
nificantly abnormal prothrombin time, fibrinogen, and/
or platelet count caused by envenomation should receive
antivenom. Patients with hypotension, systemic bleeding,
or other systemic venom effects should receive antive-
nom emergently. Any degree of true neurotoxicity,
including localized fasciculations or myokymia, is an
indication for antivenom administration. Some patients
may present with symptoms attributable to anxiety; in
the absence of signs of progressive envenomation, these
patients can be reassured and observed.
Antivenom administration (box 4)
Antivenom dosing is titrated to clinical response. The
targeted clinical response is often termed, “initial control
of the envenomation syndrome,” and consists of arrest
of the progression of local tissue venom effects, a clear
trend toward improvement in any hematologic venom
effects, and resolution of all systemic venom effects
(excluding fasciculations or myokymia, which may be
refractory to antivenom [7,11]. An initial dose of 4 to 6
vials was chosen for the premarketing trials because of
equivalent binding capacity to then-standard doses of
equine antivenom and was shown to be effective in two
premarketing studies [11,12]. Subsequent experience has
shown that most victims of rattlesnake envenomation
achieve initial control with one or two such doses, while
most copperhead snake victims can be successfully trea-
ted with a single 4-vial dose [39,40]. Very few patients
continue to experience progressive venom effects after
18 vials of antivenom [36,41]. However, with the excep-
tion of a single case report, patients who did not achieve
initial control after 20 vials of antivenom do not
respond to subsequent doses [26,29,30,36]. Panel mem-
bers noted that inexperienced health care providers
sometimes use large doses of antivenom in an attempt
to treat clinical effects that did not respond to therapy,
but could be safely observed. The reason for limiting
initial dosing to 4 to 6 vials is primarily cost, but also
the theoretical increased risk of serum sickness with lar-
ger protein loads. Initial control doses of less than 4
vials have not been well studied.
Antivenom should be administered via intravenous
infusion. In animal studies, the combination of subcuta-
neous and intravenous administration of antivenom was
no better than intravenous administration alone [42].
Skin testing is not necessary or recommended prior to
administration of the current antivenom [7,43]. In addi-
tion to cleavage and removal of the immunogenic Fc
portion of the immunoglobulin molecule, the currently
available antivenom undergoes column affinity purifica-
tion. Symptoms of acute anaphylactoid reactions, such
as pruritus, urticaria, or wheezing occur in approxi-
mately 6% of patients [37,44]. Most cases are mild and
do not preclude continued administration of antivenom.
However, severe acute allergic reactions, including reac-
tions involving airway compromise, have been described
[37,45]. As a result, the panel recommends that the first
dose of antivenom be administered in a clinical setting,
such as an emergency department or intensive care unit,
where the medications, equipment, and skilled personnel
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required to manage an airway emergency are immedi-
ately available. If there is no acute reaction to initial
dosing, subsequent doses of antivenom can be adminis-
tered in a less monitored setting, such as a hospital
ward. Management of allergic effects is discussed below.
The panel recommended increasing the initial dose of
antivenom to 8 to 12 vials in patients who present with
immediately life-threatening venom effects, such as
shock or serious active bleeding. In a large Phase IV
study of severely envenomated pit viper victims
(approximately 13% of the patients who were treated
with antivenom), 69% of patients required more than
one dose of antivenom to achieve initial control [37].
The median dose of antivenom used to achieve initial
control in this population was 9 vials (interquartile
range: 6 to 15 vials). Additionally, bites by large rattle-
snakes are associated with more severe envenomation
that requires administration of higher doses of antive-
nom [46]. In the presence of immediately life-threatening
venom effects, the panel believed that the benefit of more
rapid control of hypotension and bleeding expected with
an aggressive dosing strategy exceeded the benefit
that could be gained by administration of a more typical
4 to 6 vial antivenom dose in patients. Although this
practice is common among the panel members, it has
not been empirically studied.
The panel recommends routine administration of
intravenous crystalloid solution to any pit viper victim
who requires antivenom. Venom causes vasodilatation
and capillary leakage, leading to relative volume deple-
tion, and antivenom infusion can cause histamine
release. Although the standard dilution of antivenom is
one dose (4 - 6 vials) in 250 ml normal saline, some
panelists choose large volumes of dilution (1000 ml) in
patients for whom there is no contraindication. In gen-
eral, each dose of antivenom is infused over one hour.
Faster infusion may be preferred for critically ill patients
who are in shock or actively hemorrhaging. Some pane-
lists start antivenom administration at a slow initial rate
(e.g. 25 ml/hr for 10 minutes), followed by an increased
infusion rate (balance of dose administered over 50 min-
utes) if no acute hypersensitivity reaction is observed,
while others prefer a single infusion rate strategy to
reduce medical errors. In the absence of data, the panel
did not make an infusion rate recommendation.
Although routine pre-treatment with antihistamines is
not generally recommended, some panelists do so as a
matter of clinical routine. No evidence bears on this
practice.
Because antivenom is intended to neutralize the dose
of injected venom, the pediatric dose of antivenom is
the same as the adult dose. Although this hypothesis
has not been critically tested, it is consistent with obser-
vation in pediatric case series [47,48].
Assessment for initial control of the envenomation
syndrome (boxes 5 and 11)
Approximately half of antivenom-treated patients
require more than one dose of antivenom to achieve
initial control [11]. Therefore, the treating physician
should examine the patient and repeat indicated labora-
tory studies soon after antivenom is administered to
evaluate for treatment response. Because fibrinogen and
platelet levels change rapidly after antivenom adminis-
tration, coagulation studies and platelet counts should
be rechecked within one hour of antivenom dosing. If
initial control of the envenomation syndrome is
achieved, the patient can be observed, either as an inpa-
tient or in a clinical observation unit, to make certain
that this clinical response is maintained. If the first dose
of antivenom does not succeed in producing initial con-
trol, the initial dose should be repeated. Failure to
achieve initial control after two doses of antivenom is
uncommon. In a large retrospective study, only 17% of
rattlesnake victims and 2% of Agkistrodon (copperhead
and water moccasin) victims required more than 12
vials of antivenom to achieve initial control, and the
presence of thrombocytopenia and neurologic venom
effects prior to antivenom therapy were independently
associated with the difficulty achieving initial control
[41,49]. Consultation with a physician, clinical toxicolo-
gist, or other expert who has specific training and exper-
tise in the management of venomous snakebite is
recommended in this and other high-risk clinical situa-
tions. Information about how to reach such an expert
can be found on the algorithm (box 12), or below.
Post-stabilization monitoring and administration of
maintenance therapy (boxes 6 and 13)
Snake envenomation is a dynamic clinical process.
Although clinical improvement virtually always follows
administration of adequate antivenom doses, recurrence
or delayed-onset of one or more venom effects occurs
in approximately half of patients treated with Fab antive-
nom [11]. Serial physician examinations and laboratory
studies are necessary to detect recurrent or delayed-onset
venom effects. When it occurs, local tissue recurrence
typically develops within 6 to 36 hours of initial control.
Recurrent local tissue effects are clinically evident to the
patient and generally respond well to re-treatment with
antivenom. The onset of recurrent or delayed-onset
hematologic venom effects is much more variable, with
most cases occurring 2 - 7 days after initial control and
some cases up to 10 days after initial control [25,36].
When antivenom is administered to treat recurrent coa-
gulopathy or thrombocytopenia, the treatment response
is generally attenuated compared with the response to
initial antivenom therapy [26,28,30,31,50-52]. Hematolo-
gic venom effects are most often clinically occult; few
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patients experience medically significant bleeding even in
the setting of profound defibrination or thrombocytope-
nia [26].
The ideal duration of hospitalization and frequency of
follow-up observations and laboratory studies is
unknown. After the first 24 hours, the marginal benefit
of continued hospitalization appears to be small, and
follow-up monitoring in the outpatient setting is appro-
priate for most patients. The panel recommends that
patients be observed in the hospital for 18 - 24 hours
following initial control of the envenomation syndrome,
with serial examinations performed approximately every
6 - 8 hours during this interval. The panel recommends
that most patients have laboratory studies (protime,
hemoglobin, platelet count, and fibrinogen level) mea-
sured twice prior to discharge: once 6 - 12 hours after
initial control, which appears to be the time at which
the risk of recurrent hematologic venom effects is great-
est, and again prior to discharge [25]. Unfavourable
trends in protime, fibrinogen, or platelet counts should
prompt additional testing. Because only 5 - 10% of cop-
perhead envenomation victims develop hematologic
venom effects at any time, it is reasonable to forego one
set of follow-up lab tests in those copperhead victims
who have never manifest coagulopathy, thrombocytope-
nia, or systemic bleeding [40].
In the current FDA-approved prescribing information,
the manufacturer of antivenom recommends administra-
tion of additional 2-vial doses of antivenom given 6, 12,
and 18 hours after initial control is achieved [43]. In a
randomized clinical trial, this practice reduced the pro-
portion of patients with recurrent local tissue effects
from 8/16 (50%) to 0/15 (0%) [11]. However, cases of
recurrent local tissue effects developing in maintenance-
treated patients have been reported [26,39,40,47]. The
cost-effectiveness of maintenance therapy is unclear; in
a randomized clinical trial, patients randomized to
receive maintenance therapy and patients randomized to
receive additional antivenom administered as needed to
treat recurrent swelling received the same median num-
ber of antivenom vials [11]. The extent to which mainte-
nance therapy reduces the risk of recurrent and delayed-
onset hemorrhagic venom effects is not precisely known.
Results of the antivenom phase III premarketing trial
appeared to show a reduction in the incidence rate of
recurrent hematologic venom effects in patients who
received maintenance therapy. In that trial, recurrent
thrombocytopenia was noted in 2/14 (14%) patients who
received maintenance antivenom therapy, compared
with 9/16 (56%) patients who did not receive mainte-
nance therapy [43]. In the same study, recurrent hypofi-
brinogenemia was noted in 2/14 (14%) of patients
receiving maintenance therapy and 7/16 (44%) of those
who did not receive maintenance. Small sample size and
the large proportion of patients in the no-maintenance
group who received rescue therapy due to recurrent
local tissue effects makes any estimate of the effect of
maintenance antivenom therapy difficult to interpret.
Furthermore, the baseline risk of hematologic venom
effects varies approximately 10-fold based on the enve-
nomating species and the initial severity of the enveno-
mation, with rattlesnake victims and patients with high
initial clinical severity apparently at the greatest risk
[26,36,40]. In a recent case series from central Arizona,
32% of patients developed new or recurrent hematologic
abnormalities after initial control [31]. Finally, the pane-
lists noted that the safety of a “watchful waiting” strat-
egy is wholly dependent on the quality and frequency of
follow-up observations, which may vary depending on
local hospital resources and staffing patterns.
In light of the above information, the practice of
administering maintenance antivenom therapy is contro-
versial. Historically, some centers recommend mainte-
nance therapy universally, while others do so in the
minority of cases [26,39,40]. Given the wide variation in
clinical practice patterns the panelists concluded that a
“one size fits all” or simplified decision rule was inap-
propriate for the question of whether to administer
maintenance therapy. The panel recommended consul-
tation with a regional poison center or local snakebite
treatment expert to assist in the determination of
whether to give maintenance antivenom therapy.
Management of patients with apparent dry bites or
minor envenomations (boxes 9 and 10)
Approximately 20 - 25% of crotaline snakebites are
“dry"; no venom effects develop [18]. Although the
majority of patients with apparent dry bites have not
been envenomated, some patients who initially present
with a wound but no other signs of envenomation (i.e.
no swelling, ecchymosis, vesicle formation, or hematolo-
gic or systemic venom effects) develop signs of enveno-
mation after a latent period of minutes to hours [53]. In
addition, some patients present with apparent minor
venom effects (ecchymosis, swelling, and/or vesicles lim-
ited to the immediate area of the bite site without sys-
temic venom effects). All panel members reported
having treated patients who presented in this manner
and subsequently developed significant progressive signs
of envenomation. To our knowledge, there are no data
to describe the typical time course or define a “safe”
period of observation after which the risk of delayed-
onset venom effects is minimal, although the best avail-
able evidence suggests that 6 hours is not long enough
in many cases [53]. Cost-benefit implications are largely
unknown. The panel members recommended that, in
general, patients with apparent non-envenomation be
observed in a health care facility for at least 8 hours,
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with repeat platelet count, prothrombin time, fibrinogen,
and hemoglobin measurement prior to discharge. Anec-
dotal evidence suggests some patients, such as children
and those with lower extremity envenomations, may
develop significant tissue effects more than 8 hours after
an apparent dry bite, and therefore may require longer
observation. Patients with apparently minor envenoma-
tion and no evidence of progression should be observed
longer, in the range of 12 - 24 hours. These observation
periods might be appropriately shortened or prolonged
based on a number of factors, including the age and
general health of the patient, bite location, envenomat-
ing species, social support available to the patient,
patient preference, and ability of the treating facility to
provide efficient and cost-effective observation services.
(Figure 2) Patients who develop no venom effects during
the observation period should be discharged with
instructions to return promptly if signs of envenomation
develop or progress.
Discharge criteria and post-discharge management
(boxes 7, 8, and 14)
Patients who have had no further progression of venom
effects during an appropriate period of observation may
be discharged when certain criteria are met. As with any
patient going home from the hospital, the patient must
be able to perform activities of daily living unassisted or
with the assistance available in the home, have adequate
pain control on oral medications, and have no other
outstanding medical issues requiring hospital care. In
addition, the patient should not have any unfavorable
trends in protime, fibrinogen levels, or platelet counts,
since deterioration in one or more of these parameters
may be an early sign of recurrent or delayed-onset
hematologic venom effects.
Following discharge, patients should be instructed to
maintain limb elevation as much as possible to speed
resolution of swelling. Progressive swelling that does not
improve with elevation or signs of abnormal bleeding,
such as gingival bleeding, easy bruising, or melena, may
be the hallmark of recurrent hematologic venom effects,
and should lead to prompt re-evaluation.
Serum sickness, a type III hypersensitivity reaction
caused by administration of exogenous proteins, is a
known complication of antivenom therapy. In prospec-
tive studies, approximately 5 - 10% of patients treated
with ovine Fab antivenom develop signs of serum sick-
ness, such as fever, rash, myalgias, and arthralgias [44].
Serum sickness following Fab antivenom administration
is generally mild and responds well to treatment with
oral antihistamines and corticosteroids. At the time of
discharge, patients should be instructed about the symp-
toms of serum sickness and given directions regarding
follow-up care should serum sickness develop.
Few data exist to inform the number and timing of
follow-up visits. In general, the panel felt that manda-
tory follow-up visits were not needed for patients who
had minimal envenomation and did not require antive-
nom administration. Similarly, because the risk of late
hematologic venom effects is small, routine follow-up of
patients with uncomplicated copperhead snake enveno-
mations who did not develop hematologic venom effects
during hospitalization is unlikely to provide clinical ben-
efit to a patient. On the other hand, patients with rattle-
snake envenomations and those who demonstrated
hematologic venom effects during the acute phase of
therapy are at high risk for late hematologic venom
effects that most often occur 2 - 7 days after antivenom
therapy [25-30,51,54,55]. Follow-up visits with labora-
tory testing are therefore recommended 2 - 3 days and
5 - 7 days after discharge, with additional visits as
needed based on signs, symptoms, and laboratory
trends.
High risk situations requiring expert consultation (box 12)
Of the crotaline victims treated with antivenom,
approximately 13% develop severe envenomation [37].
Clinicians who practice outside of referral centers that
see a large volume of snakebite patients rarely have the
opportunity to develop a large base of experience treat-
ing critically envenomated patients. For this reason, the
panel identified certain high-risk clinical situations in
which consultation with a physician who has specific
training and expertise in the management of crotaline
snakebite is strongly encouraged. In institutions where
bedside consultation is available, bedside consultation
should be sought. In the remainder of institutions, tele-
phone consultation, facilitated by a regional poison cen-
ter, is recommended. Even if local practice calls for
Factors
Signs of EnvenomationApparent Dry Bite Signs of Mild Envenomation
Social SupportGood Little
SnakeCopperhead Rattlesnake
LimbUpper Lower
Age & HealthHealthy Adult Child, Elderly, or Comorbidities
4 Hours 8 Hours 12 Hours 16 Hours 24 Hours
Figure 2 Factors Influencing Observation Time for Patients
with Apparent Dry Bites and Initially Minor Envenomations
Managed Without Antivenom.
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transfer of patients from the presenting facility to a ter-
tiary care center, early consultation with a physician-
expert (or, alternatively, a pharmacologist or clinical tox-
icologist with specific training and expertise in snakebite
management) is recommended to ensure that early
interventions are ideal and all appropriate preparations
are made at the receiving facility.
Patients with life-threatening envenomation
Frank hypotension, active hemorrhage, and airway
edema are uncommon but life-threatening manifesta-
tions of crotaline snakebite [37]. Evidence supports a
benefit from antivenom therapy in the former two situa-
tions, while the use of antivenom combined with active
airway management is recommended for the latter situa-
tion based on case reports [26,36,37,56]. For the reasons
previously described, the panel recommended a larger
initial dose of antivenom for patients with shock or
active hemorrhage due to snakebite. Only 1% of snake
envenomations involve the head or neck, but the experi-
ence of panel members suggests a high risk of subse-
quent loss of airway. This situation is considered
analogous to thermal airway burns, in which early endo-
tracheal intubation may prevent the need for surgical
airway placement and its attendant complications.
Difficult to control envenomations
Even in a severely envenomated cohort, initial control of
the envenomation syndrome can be achieved with one
or two doses of antivenom in most patients [37]. Case
reports of refractory neurotoxicity and hematologic toxi-
city exist, but the available evidence do not define a
point at which further administration of antivenom is
likely to be futile [26,33,37,50]. In addition to assisting
with cost-benefit estimation, a physician-expert may be
able to identify secondary complications (e.g. rhabdo-
myolysis from persistent myokymia) that require
additional interventions. Consultation with a physician-
expert is recommended in cases where initial control of
the envenomation syndrome has not been achieved fol-
lowing two doses of antivenom.
Recurrent or delayed-onset of venom effects
As described above, the management of recurrent or
delayed-onset hematologic venom effects is controver-
sial. Most patients tolerate hematologic venom effects
well, but several serious cases and one fatality have been
described [27]. Compared to the initial treatment
response, the response to repeat antivenom dosing is
often attenuated and may be transient [26,28,50,52].
While guidelines exist, there is no settled clinical deci-
sion rule for which patients require retreatment, and
estimates of which patients are at highest risk are largely
derived from experience with other diseases [57].
Although the risk to the patient of additional antivenom
dosing appears to be minimal, cost-benefit considera-
tions are significant, particularly when re-hospitalization
is required. For these reasons, the panel recommends
direct consultation with a physician-expert to assist in
management of these patients.
Allergic reactions to antivenom
Signs of immediate hypersensitivity to antivenom are
observed in 5 - 6% of patients treated with ovine Fab
antivenom [37,44]. Although most of these reactions are
relatively minor and do not preclude antivenom therapy,
some are severe. As described above, the initial manage-
ment of a hypersensitivity reaction is straightforward:
halt the antivenom infusion and administer antihista-
mines, corticosteroids, and fluids as needed until signs
of hypersensitivity have resolved. Epinephrine may be
required for severe reactions. At this point, the decision
to resume or discontinue antivenom therapy involves a
complex balancing of risk and benefit that the panel
could not reduce to an algorithm. Because few clinicians
have the opportunity to gain experience with this
uncommon clinical scenario, consultation with an expert
clinician is recommended.
Hematologic venom effects when transfusion is considered
Thrombin-like enzymes in crotaline venom incompletely
cleave fibrinogen, leading to the formation of an unstable
fibrin clot that is not cross-linked [23,58]. The mechan-
ism that underlies venom-induced thrombocytopenia is
less well-understood; venom-induced injury to platelet
cell membranes and endothelial activation caused by
microvascular damage have been proposed [24,58,59].
Transfusion alone can produce transient improvement in
coagulation parameters and platelet counts, but rarely
has a sustained effect unless adequate doses of antivenom
have also been administered. Aggressive antivenom
administration should always precede fresh frozen
plasma, cryoprecipitate, or platelet transfusion if antive-
nom is available. Transfusion is indicated for cases in
which medically significant bleeding is occurring.
Whether administration of additional antivenom and
transfusion are appropriate for patients who are not
actively bleeding but who have profound coagulopathy,
profound thrombocytopenia, or multicomponent hema-
tological venom effects (both thrombocytopenia and defi-
brinogenation) remains unclear [60]. Although most
patients tolerate hematological venom effects without
incident, severe or fatal bleeding events have occurred
[27-31]. Transfusion also has associated cost and risks.
Consultation prior to transfusion is recommended, when
possible, to maximize the utility of transfusion and
reduce unnecessary use of blood products.
Rhabdomyolysis
Although crotaline venom is directly myotoxic, clinically
severe rhabdomyolysis is uncommon in the United
States [61]. Although routine creatine kinase measure-
ment is not recommended, specific patients, such as
those with severe local tissue injury and/or prolonged
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systemic neurotoxicity can develop rhabdomyolysis.
Consultation with a physician-expert is recommended in
these cases.
Suspected compartment syndrome
Crotaline snakebite can produce pain, swelling, indura-
tion, paresthesias, color changes (e.g. bluish discolora-
tion from bruising), difficult-to-palpate pulses, and
tenderness in the envenomated extremity, mimicking
the initial signs of compartment syndrome. However,
true compartment syndrome is much less common, and
a prospective observational study in humans showed
that most rattlesnake victims have greater blood flow in
the envenomated than in the non-envenomated limb
[62]. Animal research and human experience demon-
strate that antivenom administration reduces compart-
ment pressures, and surgical groups who used to
perform fasciotomy frequently now acknowledge that
antivenom administration often precludes the need for
fasciotomy [9,40,63,64]. In one large case series of
patients treated in a tertiary referral center, only 8/236
(3.4%) of patients received a fasciotomy or digital der-
motomy [10]. Measurement of compartment pressure
prior to consideration of fasciotomy is recommended.
Compartment pressure measurement may not be feasi-
ble in cases of digital envenomation. Consultation with
a physician-expert is recommended whenever compart-
ment syndrome is suspected and prior to any fasciotomy
or digit dermotomy.
Venom-induced hives and angioedema
Anaphylactic and anaphylactoid reactions to venom are
uncommon manifestations of snakebite which can range
in severity from urticarial rash to multisystem organ fail-
ure and angioedema causing airway loss [65]. At least
2 deaths have been reported [66,67]. Although standard
therapy includes antihistamines, steroids, epinephrine,
and antivenom, the ideal management of this condition
is unknown. Because these patients are often critically ill
and require aggressive, multimodal therapy, panel mem-
bers recommended expert consultation.
Complicated wound issues
Crotaline envenomation causes local tissue necrosis by
a variety of mechanisms, some of which are not rever-
sible with antivenom therapy [68]. Although venom-
induced inflammation often mimics infection, true bac-
terial cellulitis is uncommon, affecting approximately
3% of snakebite patients [69]. Rarely, severe infections
have been reported [70]. Confusion about whether an
envenomated extremity is inflamed or infected may
lead to unnecessary medical care, including intrave-
nous antibiotics and prolonged hospitalization [71].
Decisions about debridement and tissue grafting may
also be complex. Consultation with an expert who has
experience managing envenomated wounds may
improve these decisions.
Treatments to avoid in pit viper snakebite (box 15)
The panel recommends against several therapies that are
commonly utilized to treat crotaline envenomation, but
which are ineffective, unnecessary, or harmful. Wound
incision and suction does not remove meaningful
amounts of venom and can worsen local tissue injury
[72,73]. Although little evidence exists to condemn the
topical application of ice, this measure appears to be
ineffective [74]. More aggressive forms of cryotherapy,
such as ice water immersion, have been associated with
severe iatrogenic tissue injury [75]. Although this issue
has not been subjected to study, panel members recom-
mended avoiding the use of non-steroidal anti-inflam-
matory drugs (NSAIDs) because of the theoretical harm
associated with the platelet dysfunction caused by
NSAIDs in a potentially thrombocytopenic patient. Pro-
phylactic antibiotics, prophylactic fasciotomy, and the
routine use of blood products should be avoided for the
reasons discussed above. Application of electrical cur-
rent from a spark plug or hand-held “stun gun” has
been recommended for therapy based on anecdotal
experience from a missionary physician in Ecuador [76].
Subsequent animal research and human experience have
shown this practice to be ineffective and associated with
significant tissue injury [77-81]. There is a paucity of
data about the role of corticosteroids in crotaline snake-
bite. Based on unpublished experience and controlled
trial data from the United States showing that corticos-
teroids do not improve outcome in old world viper
(family Viperidae, subfamily Viperidae) envenomation,
administration of corticosteroids is reserved for treat-
ment of hypersensitivity phenomena [82,83].
Although data from envenomations by snakes native
to the United States are lacking, arterial tourniquet
application is ineffective and sometimes associated with
apparent harm when used to treat South American cro-
taline snakes [84]. Although pressure immobilization has
a confirmed role in the management of highly neuro-
toxic elapid snake envenomations, its role in crotaline
envenomation is unclear. In porcine models of severe
western diamondback rattlesnake envenomation, pres-
sure immobilization prolonged survival, with varying
effects on local tissue injury [85,86]. Similarly, lymphatic
constricting bands reduce the absorption of venom into
the systemic circulation in animal models, but whether
this strategy is more likely to improve or worsen overall
outcomes is unknown [87]. Neither pressure immobili-
zation nor use of lymphatic constricting bands is
recommended.
Discussion
Management of a simple case of crotaline snakebite
involves many clinical decisions. Clinical trials in this
area are challenging to conduct. To our knowledge, only
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five clinical trials of crotaline snakebite have been per-
formed. One of these was randomized [11]. A second
randomized trial was attempted, but terminated early
due to low enrollment [88]. A third identified trial was
non-randomized [12]. Finally, two trials were identified
involving an antivenom product that is not currently
licensed in the US. One of these trials has been com-
pleted, but results have only been published in prelimin-
ary form [89]. The other is ongoing [90].
In situations where high quality evidence does not
exist, clinical recommendations can be primarily influ-
enced by factors other than the results of clinical trials.
These factors include uncertainty in the estimates of
likely benefit, risk, inconvenience, and cost of therapy,
and varying values of clinicians and patients [91]. Avail-
able techniques for evidence-based decision-making do
not provide tools for dealing with regional variations in
disease characteristics, differences in treatment resources
available at different centers, or situations in which the
amount of unpublished experience equals or exceeds the
amount of data in the peer-reviewed literature. By defini-
tion, evidence-based hypothesis testing cannot begin
until each specific clinical question is defined; this creates
a circular problem when creating complex, highly-
branched treatment algorithms. For these reasons, we
believed that an evidence-informed structured consensus
process would produce a final result that was more useful
to clinicians and patients than a formal evidence-based
medicine approach. Notwithstanding these limitations, it
is possible to describe these treatment recommendations
in GRADE terms [91]. The decision to give antivenom to
patients with limb-threatening envenomation or severe
systemic effects is a strong recommendation based on
moderate quality evidence; despite the lack of placebo-
controlled trials, concordant results of a large number of
observational studies and animal experiments make it
clear that the benefits of therapy outweigh the associated
risks and burdens. All other recommendations are weak
recommendations based on very low quality evidence.
This process, and its output, have limitations.
Although we took care to minimize the introduction of
commercial bias through conflict-of-interest disclosure,
exclusion of the project sponsor from the decision-mak-
ing process, diversity of panel membership, use of a
trained facilitator, and structured decision-making meth-
ods, we cannot exclude the possibility that prior rela-
tionships between project participants and the
manufacturer of antivenom may have influenced the
opinions and practice patterns of panel members. These
concerns may be mitigated somewhat by the observation
that, although the treatment algorithm contained here is
more comprehensive than recently published treatment
guidance from unrelated authors, the indications for
antivenom are essentially similar [9,92,93].
Rather than rely solely on expert opinion, we utilized
several strategies to inform the decision-making process.
We performed a comprehensive literature review and
made all publications containing original data available
at the time of panel deliberations. In addition, we uti-
lized our gap analysis to identify data needs and develop
information targeted to those needs. To this end, we
performed focused analysis of line-level data collected in
the phase II and III clinical trials, a phase IV database
created by the antivenom manufacturer, and a separate
prospectively-collected database from a high-volume
snakebite treatment center. Whenever the above meth-
ods did not produce clear data to inform a treatment
decision, we explicitly acknowledged this limitation in
the manuscript.
Conclusions
Venomous snakebite is a complex and dynamic clinical
entity that is characterized by a wide variation in clinical
effects and response to therapy. Using a structured, evi-
dence-informed decision-making process, we provide
treatment guidelines that may reduce unnecessary varia-
tion in care and improve clinical outcomes.
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